Review Article
Volume 12 Issue 8 - 2020
Bipolar Disorder: Diagnosis, Pathophysiology and Therapy
Agrim Jain*
Department of Clinical Research, School of Biological and Biomedical Sciences, Galgotias University, Greater Noida, UP, India
*Corresponding Author: Agrim Jain, Department of Clinical Research, School of Biological and Biomedical Sciences, Galgotias University, Greater Noida, UP, India.
Received: May 29, 2020; Published: July 23, 2020




Abstract

Bipolar disorder is a mental illness that causes dramatic shifts in a person’s mood, energy and ability to think clearly. People with bipolar experience high and low moods-known as mania and depression-which differ from the typical ups-and-downs most people experience. People often undergo lack of energy to sometimes their energy levels touching the zenith. The person is sometimes in the feeling of sudden guilt and sometimes in the feeling of inflated self-esteem.

There are various symptoms that can be observed in a person and can be noted in order to diagnose the bipolar disorder in a person. Certain depression episodes prolong stress or anxiety, mania and hypomania can lead to bipolar disorder. The various neurological disorders can also be responsible for the cause of the disease. The neurotransmitter imbalance is one of the major causes of the bipolar disorder. Other major causes are the genetic and environmental factors which also lead to the formation of this syndrome in a person.

The need of absolute and perfect medication for the bipolar disorder is the foremost priority. No research or study could find out the exact treatment for the bipolar disorder. Treatment is usually lifelong and often involves a combination of medications and psychotherapy.

Keywords: Bipolar Disorder; Stress; Mania; Hypomania; Depression; Catechol-O-methyltransferase

References

  1. MW Jann. “Diagnosis and treatment of bipolar disorders in adults: A review of the evidence on pharmacologic treatments”. American Health and Drug Benefits 7.9 (2014): 489-499.
  2. J Tiihonen., et al. “Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia”. JAMA Psychiatry 74.7 (2017): 686-693.
  3. R Cooper. “Diagnostic and statistical manual of mental disorders (DSM)”. Knowledge Organization (2017).
  4. B Pavlova., et al. “Lifetime prevalence of anxiety disorders in people with bipolar disorder: A systematic review and meta-analysis”. The Lancet Psychiatry 2.8 (2015): 710-717.
  5. E Brietzke., et al. “A theoretical framework informing research about the role of stress in the pathophysiology of bipolar disorder”. Progress in Neuro-Psychopharmacology and Biological Psychiatry (2012).
  6. A Caspi., et al. “Influence of life stress on depression”. Science 80 (2003): 386-389.
  7. JS Manning. “Tools to improve differential diagnosis of bipolar disorder in primary care”. The Primary Care Companion to The Journal of Clinical Psychiatry 12.1 (2010): 17-22.
  8. AM Kilbourne., et al. “Burden of general medical conditions among individuals with bipolar disorder”. Bipolar Disorders 6.5 (2004): 368-373.
  9. F Benazzi. “Bipolar II disorder: Epidemiology, diagnosis and management”. CNS Drugs 21.9 (2007): 727-740.
  10. E Vieta., et al. “A European perspective on the Canadian guidelines for bipolar disorder”. Bipolar Disorders 7.3 (2005): 73-76.
  11. CL Bowden., et al. “Practice guideline for the treatment of patients with bipolar disorder (revision)”. American Journal of Psychiatry 159.4 (2002): 1-50.
  12. RMA Hirschfeld., et al. “Perceptions and impact of bipolar disorder: How far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 Survey of individuals with bipolar disorder”. Journal of Clinical Psychiatry 64.2 (2003): 161-174.
  13. R Hunter., et al. “Bipolar disorder - Aetiology and pathophysiology”. Hospital Pharmacist (2004).
  14. JM Gill., et al. “Using electronic health record-based tools to screen for bipolar disorder in primary care patients with depression”. Journal of the American Board of Family Medicine 25.3 (2012): 283-290.
  15. MW Jann. “Implications for atypical antipsychotics in the treatment of schizophrenia: Neurocognition effects and a neuroprotective hypothesis”. Pharmacotherapy 24.12 (2004): 1759-1783.
  16. P McGuffin., et al. “The heritability of bipolar affective disorder and the genetic relationship to unipolar depression”. Archives of General Psychiatry 60.5 (2003): 497-502.
  17. DJ Miklowitz and SL Johnson. “The Psychopathology and Treatment of Bipolar Disorder”. Annual Review of Clinical Psychology 2 (2006): 199.
  18. S Hodgins., et al. “Children of parents with bipolar disorder: A population at high risk for major affective disorders”. Child and Adolescent Psychiatric Clinics of North America 11.3 (2002): 533-553.
  19. PH Wender., et al. “Psychiatric Disorders in the Biological and Adoptive Families of Adopted Individuals With Affective Disorders”. Archives Of General Psychiatry 43.10 (1986): 923-929.
  20. W Berrettini. “Evidence for shared susceptibility in bipolar disorder and schizophrenia”. American Journal of Medical Genetics 123.1 (2003): 59-64.
  21. RM Murray., et al. “A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder”. Schizophrenia Research 71.1-2 (2004): 405-416.
  22. LJ Siever and KL Davis. “Overview: Toward a dysregulation hypothesis of depression”. American Journal of Psychiatry (1985).
  23. DS Charney., et al. “Receptor Sensitivity and the Mechanism of Action of Antidepressant Treatment: Implications for the Etiology and Therapy of Depression”. Archives of General Psychiatry 38.10 (1981): 1160-1180.
  24. CA Stockmeier. “Involvement of serotonin in depression: Evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter”. Journal of Psychiatric Research 37.5 (2003): 357-373.
  25. A Anand., et al. “Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients”. The American Journal of Psychiatry 157.7 (2000): 1108-1114.
  26. CA Naranjo., et al. “The role of the brain reward system in depression”. Progress in Neuro-Psychopharmacology and Biological Psychiatry 25.4 (2001): 781-823.
  27. KW Sax and SM Strakowski. “Behavioral sensitization in humans”. Journal of Addictive Diseases (2001): 55-65.
  28. TE Robinson and JB Becker. “Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis”. Brain Research Reviews 396.2 (1986): 157-198.
  29. PW Kalivas., et al. “Behavioral and neurochemical effects of acute and daily cocaine administration in rats”. Journal of Pharmacology and Experimental Therapeutics 245.2 (1988): 485-492.
  30. JR Geddes and DJ Miklowitz. “Treatment of bipolar disorder”. The Lancet (2013).
  31. JR Geddes., et al. “Long-Term Lithium Therapy for Bipolar Disorder: Systematic Review and Meta-Analysis of Randomized Controlled Trials”. American Journal of Psychiatry 161.2 (2004): 247-222.
  32. LV Kessing., et al. “Valproate v. lithium in the treatment of bipolar disorder in clinical practice: Observational nationwide register-based cohort study”. British Journal of Psychiatry (2011): 57-63.
  33. DR Goldsmith., et al. “Lamotrigine: A review of its use in bipolar disorder”. Drugs 63.19 (2003): 2029-2050.
  34. F Ng., et al. “The role of lamotrigine in the management of bipolar disorder”. Neuropsychiatric Disease and Treatment 3.4 (2007): 463-474.
  35. RB Sassi., et al. “Increased gray matter volume in lithium-treated bipolar disorder patients”. Neuroscience Letters 329.2 (2002): 243-245.
  36. RA Kowatch., et al. “Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder”. Journal of the American Academy of Child and Adolescent Psychiatry 39.6 (2000): 713-720.
  37. SN Ghaemi and JJ Katzow. “The use of quetiapine for treatment-resistant bipolar disorder: A case series”. Annals of Clinical Psychiatry 11.3 (1999): 137-140.
  38. E Vieta., et al. “Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: A randomized, double-blind, placebo-controlled study”. Bipolar Disorders 9.4 (2007): 413-425.
  39. LL Davis., et al. “Divalproex in the treatment of bipolar depression: A placebo-controlled study”. Journal of Affective Disorders 85.3 (2005): 259-266.
  40. KD Denicoff., et al. “Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder”. The Journal of Clinical Psychiatry 58.11 (1997): 470-478.
  41. WA Nolen. “Carbamazepine, a possible adjunct or alternative to lithium in bipolar disorder”. Acta Psychiatrica Scandinavica 67.4 (1983): 218-225.
  42. A Cipriani., et al. “Olanzapine in long-term treatment for bipolar disorder”. Cochrane Database of Systematic Reviews 24.12 (2009): 1729-1738.
  43. SL McElroy., et al. “Olanzapine in treatment-resistant bipolar disorder”. Journal of Affective Disorders 49.2 (1998): 119-222.
  44. A Vasudev., et al. “Oxcarbazepine in the maintenance treatment of bipolar disorder”. Cochrane Database of Systematic Reviews (2008): CD005171.
  45. A Vasudev., et al. “Oxcarbazepine for acute affective episodes in bipolar disorder”. The Cochrane Database of Systematic Reviews (2011).
  46. P Montgomery and AJ Richardson. “Omega-3 fatty acids for bipolar disorder”. Cochrane Database of Systematic Reviews (2008).
  47. AL Stoll., et al. “Omega-3 fatty acids and bipolar disorder: A review”. Prostaglandins Leukotrienes and Essential Fatty Acids 60.5-6 (1999): 329-337.
  48. JR Calabrese., et al. “Fish oils and bipolar disorder: A promising but untested treatment”. Archives of General Psychiatry 56.5 (1999): 413-414.
  49. YS Woo., et al. “Lurasidone as a potential therapy for bipolar disorder”. Neuropsychiatric Disease and Treatment (2013): 1521-1529.
  50. RH Belmaker. “Lurasidone and bipolar disorder”. American Journal of Psychiatry (2014).
  51. MA Frye., et al. “Clozapine in bipolar disorder: Treatment implications for other atypical antipsychotics”. Journal of Affective Disorders 48.2-3 (1998): 91-104.
  52. A Ciapparelli., et al. “Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: A naturalistic 48-month follow-up study”. The Journal of Clinical Psychiatry 64.4 (2003): 451-458.
  53. S Derry and RA Andrew. “Atypical antipsychotics in bipolar disorder: Systematic review of randomised trials”. BMC Psychiatry 7 (2007): 40.
  54. KD Chang. “The use of atypical antipsychotics in pediatric bipolar disorder”. Journal of Clinical Psychiatry 4 (2008): 4-8.
  55. T Suppes., et al. “Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression”. Journal of Affective Disorders (2010): 485-493.
  56. ME Thase., et al. “Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (the BOLDER II study)”. Journal of Clinical Psychopharmacology 26.6 (2006): 600-609.
  57. E Vieta., et al. “Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: A meta-analysis of randomized controlled trials”. The International Journal of Neuropsychopharmacology 14.8 (2011): 1029-1049.
  58. CL Bowden and V Singh. “Valproate in bipolar disorder: 2000 Onwards”. Acta Psychiatrica Scandinavica 426 (2005): 13-20.
  59. CL Bowden and V Singh. “Valproate: Clinical Pharmacological Profile”. in Bipolar Psychopharmacotherapy: Caring for the Patient: Second Edition (2011).
  60. LN Yatham. “A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder”. Journal of Affective Disorders 128 (2011): 21-28.
  61. RS McIntyre. “Aripiprazole for the maintenance treatment of bipolar I disorder: A review”. Clinical Therapeutics 7 (2010): 319-323.
  62. L Warrington., et al. “Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder”. CNS Drugs 21.10 (2007): 835-849.
  63. RL Findling., et al. “Efficacy, long-term safety, and tolerability of Ziprasidone in children and adolescents with bipolar disorder”. Journal of Child and Adolescent Psychopharmacology 23.8 (2013): 545-557.
  64. M Haas., et al. “Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: A randomized, double-blind, placebo-controlled study”. Bipolar Disorders 11.7 (2009): 687-700.
  65. GA Carlson., et al. “Liquid risperidone in the treatment of rages in psychiatrically hospitalized children with possible bipolar disorder”. Bipolar Disorders 12.2 (2010): 205-212.
  66. S Loganathan. “Chlorpromazine-induced skin pigmentation with short-term use in a patient with bipolar disorder: A case report [4]”. Primary Care Companion to the Journal of Clinical Psychiatry 9.4 (2007): 316-317.
  67. M Tohen., et al. “Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression”. Archives Of General Psychiatry 60.11 (2003): 1079-1088.
  68. PE Keck., et al. “Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression”. The Journal of Clinical Psychiatry 66.5 (2005): 611-616.
  69. I Pacchiarotti., et al. “The International Society for bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders”. The American Journal of Psychiatry 170.11 (2013): 1249-1262.
  70. L Tondo., et al. “Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders”. Acta Psychiatrica Scandinavica 127.5 (2013): 355-364.
  71. G Vázquez., et al. “Comparison of antidepressant responses in patients with bipolar vs. unipolar depression: A meta-analytic review”. Pharmacopsychiatry 44.1 (2011): 21-26.
  72. BH Amit and A Weizman. “Antidepressant treatment for acute bipolar depression: An update”. Depression Research and Treatment (2012): 684725.
  73. KR Connolly and ME Thase. “The clinical management of bipolar disorder: A review of evidence-based guidelines”. The Primary Care Companion to The Journal of Clinical Psychiatry (2011): 10r01097.
  74. U Mccormick., et al. “Diagnosis and treatment of patients with bipolar disorder: A review for advanced practice nurses”. Journal of the American Association of Nurse Practitioners 27.9 (2015): 530-542.
  75. VP Kamboj. “Herbal medicine”. Current Science 78.1 (2000): 35-39.
  76. S Bent and R Ko. “Commonly used herbal medicines in the United States: A review”. American Journal of Medicine 116.7 (2004): 478-485.
  77. NJ Gogtay., et al. “The use and safety of non-allopathic Indian medicines”. Drug Safety 25.14 (2002): 1005-1019.
  78. V Gupta., et al. “Therapeutic efficacy of Phytochemicals as anti-anxiety-a review”. Journal of Pharmacy Research (2010).
  79. E Wiebe. “A randomized trial of aromatherapy to reduce anxiety before abortion”. Effective Clinical Practice 3.4 (2000): 166-169.
  80. J Edge. “A pilot study addressing the effect of aromatherapy massage on mood, anxiety and relaxation in adult mental health”. Complementary Therapies in Nursing and Midwifery 9.2 (2003): 90-97.
  81. SM Wilkinson., et al. “Effectiveness of aromatherapy massage in the management of anxiety and depression in patients with cancer: A multicenter randomized controlled trial”. Journal of Clinical Oncology 25.5 (2007): 532-539.
  82. D Keaton., et al. “Utilization of herbal and nutritional compounds among older adults with bipolar disorder and with major depression”. International Journal of Geriatric Psychiatry 24.10 (2009): 1087-1093.
  83. R Bauer. “Damiana”. Zeitschrift fur Phyther (2017).
  84. JH Baek., et al. “Clinical applications of herbal medicines for anxiety and insomnia; Targeting patients with bipolar disorder”. Australian and New Zealand Journal of Psychiatry (2014).
  85. S Weng., et al. “Comparison of the Addition of Siberian Ginseng (Acanthopanax senticosus) Versus Fluoxetine to Lithium for the Treatment of Bipolar Disorder in Adolescents: A Randomized, Double-Blind Trial”. Current Therapeutic Research 68.4 (2007): 280-290.
  86. JS Cauffield and HJ Forbes. “Dietary supplements used in the treatment of depression, anxiety, and sleep disorders”. Lippincott’s Primary Care Practice 3.3 (1999): 290-304.
  87. K Linde., et al. “St John’s wort for major depression”. Cochrane Database of Systematic Reviews (2008).
  88. EA Apaydin., et al. “A systematic review of St. John’s wort for major depressive disorder”. Systematic Reviews (2016).
Citation: Agrim Jain. “Bipolar Disorder: Diagnosis, Pathophysiology and Therapy”. EC Neurology 12.8 (2020): 136-149.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


July Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the July issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before August 09, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk